Amyloid debates and peptide policy drive biotech news
TL;DR Summary
FDA plans advisory panels to reconsider compounded peptides; a sweeping Cochrane review revives debates over amyloid-targeting Alzheimer’s drugs; Roche will run another Elevidys trial outside the U.S. as Sarepta markets it domestically; Lilly’s Foundayo GLP-1 pill shows non-inferiority to insulin glargine with a FDA submission planned by the end of Q2.
- Cochrane review reignites Alzheimer’s amyloid wars statnews.com
- Analysis of Alzheimer’s Drugs Stirs Debate About Their Effectiveness The New York Times
- Alzheimer's Drug Review Ignites Backlash From Experts MedPage Today
- Alzheimer’s Drugs Targeting Amyloid Don’t Help, Review Finds Bloomberg.com
- Effect of ‘gamechanger’ Alzheimer’s drugs ‘trivial’, review concludes | Dementia The Guardian
Reading Insights
Total Reads
1
Unique Readers
2
Time Saved
2 min
vs 3 min read
Condensed
89%
457 → 51 words
Want the full story? Read the original article
Read on statnews.com